New EU Template for Clinical Trial Recruitment and Informed Consent: What Pharma Teams Need to Know

New EU Template for Clinical Trial Recruitment and Informed Consent: What Pharma Teams Need to Know

The European Medicines Agency (EMA) has introduced a new harmonised template for participant recruitment and informed consent procedures in clinical trials. This article explains the key changes, their impact on pharmaceutical companies, and answers frequently asked questions. For BD and strategy teams, the shift signals a faster path to multi-country approvals but also a looming dual-compliance burden that demands immediate operational attention. The new Informed consent research template is the centerpiece of this regulatory update.

IntelligenceRegulatory Impact▾

EMA are the bodies to watch. Regulatory relevance reads medium for this therapeutic area. Teams should track submission types, designations, and any guidance shifts that could move approval timelines.

Key Takeaways

• The EMA has introduced a harmonised EU template for participant recruitment and informed consent, effective immediately under the Clinical Trials Regulation (CTR).
• The template explicitly addresses digital formats, AI tools, and video/audio files for communication — a first for EU-wide guidance.
• It is mandatory for all clinical trial applications submitted via CTIS; legacy trials under Directive 2001/20/EC must comply with older rules until 30 January 2025.
• Pharma teams should update their standard operating procedures (SOPs) and consent form templates now to avoid regulatory delays in the transition period.

IntelligenceCompetitive Intelligence▾

Competitive pressure is high. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

The Development

The European Commission, in coordination with the EMA, has released a new standard template for specifying recruitment and informed consent procedures in clinical trials. The template was developed to fulfil the requirements of the Clinical Trials Regulation (CTR) (Chapter V, Annex I K and L) and covers recruitment and informed consent procedures, including the use of digital formats, AI tools, and video and audio files for communication. The template is designed to harmonise practices across EU/EEA member states, replacing the previous fragmented approach under Directive 2001/20/EC. The CTR became applicable on 31 January 2022, but the Directive still applies until 30 January 2025 for trials submitted before that date.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance medium. Expect implications for this therapeutic area pricing, access, and launch sequencing.

Implications for Pharma Teams

For pharmaceutical companies and CROs, this new template introduces both operational and strategic implications. Operationally, teams must update their informed consent form (ICF) templates and recruitment materials to align with the new structure, which now explicitly includes digital and AI-driven methods. This may require investment in eConsent platforms and AI compliance checks. Strategically, the harmonisation reduces regulatory variability across EU states, potentially speeding up trial approvals for sponsors who adopt the template early. However, the transition period until January 2025 means that legacy trials under the Directive must still comply with older rules, creating a dual-compliance burden. BD and strategy teams should assess the competitive advantage of early adoption, especially for multi-country trials, and monitor competitor filings in CTIS for benchmarking.

The template covers recruitment and informed consent procedures, including the use of digital formats, AI tools and video and audio files for communication. For pipeline analysts comparing competitive programs, the key differentiator will be how quickly a sponsor can pivot to the new template and demonstrate compliance with the 7 major components of an informed consent — title of the study, names and affiliations of the primary investigator, purpose, subject selection criteria, study procedures, potential risks and discomforts, and potential benefits — now embedded in a harmonised EU framework.

Frequently Asked Questions

Related coverage

• EMA, AMA and African Regulators Unite to Accelerate Ebola Clinical Trials
• Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight — regulatory updates
• Circulating Biomarkers: Additional Evidence Supporting Their Clinical Use in Breast Cancer